PARIS--(BUSINESS WIRE)--Regulatory News:
Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO)
Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):
Total number of
|Total number of voting rights|
|August 31, 2015||40, 552, 083||
Theoretical number of voting rights: 40, 552, 083
Number of real voting rights: 40, 510, 182 (without
At August 31, 2015, the Company’s capital stands at €10,138,020.75.
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.
Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive complete results of the Phase II trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com